Improving Medication Adherence in Adolescents Who Had a Liver Transplant (iMALT)

September 9, 2026 updated by: Eyal Shemesh, Icahn School of Medicine at Mount Sinai

The study's aim is to test a tailored telemetric intervention to reduce rejection incidence by improving medication adherence in a group of adolescent liver transplant recipients identified as nonadherent by a marker (the Medication Level Variability Index, MLVI).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a prospective, multi-center, randomized controlled trial. The study will be conducted in transplant centers in the United States and Canada. Estimated final sample size of 140 after attrition. Pediatric adolescent and young adult (age at enrollment ≥12 and < 20) transplant recipients will be eligible for participation in the study. Eligible participants will be randomly assigned to intervention or control group. An interim analysis to evaluate efficacy will be performed. Missing data will not be imputed for secondary analyses.

Study Type

Interventional

Enrollment (Actual)

148

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ontario
      • Toronto, Ontario, Canada, M5G1X8
        • The Hospital For Sick Children Toronto
    • California
      • Los Angeles, California, United States, 90027
        • Children's Hospital Los Angeles
      • Los Angeles, California, United States, 90095
        • Mattel Children's Hospital UCLA
      • San Francisco, California, United States, 94107
        • Benioff Children's Hospital UCSF
    • Florida
      • Miami, Florida, United States, 33136
        • Miami Transplant Institute
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Children's Healthcare of Atlanta/Emory
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Lurie Children's Hospital
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • C.S.Mott Children's Hospital
    • New York
      • New York, New York, United States, 10032
        • Columbia University Medical Center
      • New York, New York, United States, 10029
        • Icahn School of Medicine at Mount Sinai
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, United States, 15224
        • Children's Hospital of Pittsburgh
    • Texas
      • Houston, Texas, United States, 77030
        • Texas Children's Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years to 19 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • The patient is ≥ 12 and < 20 years of age at enrollment.
  • ≥2.5 years after last liver transplantation.
  • Guardian's consent, adolescent assent at enrollment.
  • The patient is prescribed tacrolimus.
  • The patient's MLVI (SD of tacrolimus) was > 2 when calculated by the site for a period of 2 years prior to the review date

Exclusion Criteria:

  • The patient has had transplant of an organ other than liver.
  • The patient is currently listed for any organ transplantation.
  • The patient is expected to transition to another service (e.g., adult clinic, another
  • hospital) during the two years of the study.
  • Pregnant patients.
  • A temporary exclusion: the patient is not medically stable or was hospitalized for >48 consecutive hours in the past three months.
  • Site PI, study PI, or Medical Monitor determines that the patient should not be a candidate for the intervention due to factors that are not covered in the above criteria.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Telemetric Intervention Arm

Adolescent with MLVI>2 to receive the telemetric intervention.

Calls, scripted by a manual; the frequency of the calls varies with patient's MLVI status and preferences.

No Intervention: Standard of Care Arm

Adolescent with MLVI>2 to receive standard of care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants Experiencing at Least One Episode of Rejection
Time Frame: 2 Years

The incidence of biopsy-proven acute cellular rejection (number of patients experiencing at least one episode of rejection) at any time during the 2 years of follow up. Biopsy-confirmed late acute rejection, as determined by the majority of 3 masked readings of liver biopsy images by 3 pathologists that are not from the clinical site at which the patient is treated. Patients with incomplete follow-up (for example due to death, re-transplant, listing for re-transplantation), was assumed to have experienced a rejection for the purpose of the primary analysis.

2 Years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Standard Deviation of A Series Of Tacrolimus Levels (MLVI)
Time Frame: 2 Years

Medication level variability index (MLVI) score is defined as the Standard Deviation (SD) Of Tacrolimus Blood Levels over time during follow-up. MLVI identifies medication-taking behavior. A higher SD indicates less consistent adherence.

2 Years
Number of Participants With Locally and Centrally Determined Rejection by Biopsy
Time Frame: 2 Years

Number of Participants with Locally and Centrally Determined Rejection Biopsy Proven Rejection

2 Years
Number of Locally Determined Rejections by Biopsy Per Patient During Follow-up
Time Frame: 2 Years

Rate Of Locally Determined Biopsy Proven Rejection determined by Number of locally determined rejections by biopsy per patient during follow-up

2 Years
Time to First Locally Rejection From Enrollment
Time Frame: about 12 months

Time to first locally determined rejection by biopsy from enrollment

about 12 months
Time to First Centrally Determined Rejection
Time Frame: up to 12 months

Time, in months, to first centrally determined rejection by biopsy from enrollment

up to 12 months
Occurrence of Death
Time Frame: 2 Years

Number of deaths

2 Years
Occurrence of Re-Listing For Transplantation
Time Frame: 2 Years

Number of participants listing for retransplantation

2 Years
Number of Participants With ALT >150 U/L
Time Frame: 2 Years

Number of Participants achieving above the predetermined threshold alanine trans aminase (ALT) > 150

2 Years
Mean and Maximal ALT Level
Time Frame: 2 Years

mean and maximal ALT (defined as in MALT as the mean of all levels recorded during the study period and the maximal level recorded during the study period)

2 Years
Number of Participants Achieving Mean GGT > 150
Time Frame: 2 Years

Number of participants achieving mean number above threshold GGT > 150 Gamma Glutamyl Transferase (gGT)

2 Years
Mean and Maximal gGT
Time Frame: 2 Years

mean and maximal gGT (defined as in MALT as the mean of all levels recorded during the study period and the maximal level recorded during the study period)

2 Years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 14, 2018

Primary Completion (Actual)

October 22, 2025

Study Completion (Actual)

October 22, 2025

Study Registration Dates

First Submitted

September 28, 2018

First Submitted That Met QC Criteria

September 28, 2018

First Posted (Actual)

October 1, 2018

Study Record Updates

Last Update Posted (Actual)

September 30, 2026

Last Update Submitted That Met QC Criteria

September 9, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • GCO 18-0061
  • U01DK119200 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe